Introduction The Epworth Sleepiness Scale (ESS) is a validated tool for capturing self-reported excessive daytime sleepiness. We examined thresholds for association between ESS changes and risk of 5-year all-cause mortality. Methods ESS values were mined from progress note-derived free form texts using a natural language processing (NLP) pipeline with reported accuracy of 91%. Veterans in the VHA diagnosed with a sleep disorder or who had participated in a sleep study from January 13, 2000, to August 13, 2018, and with two exams at least 12 weeks apart were identified. Patients were categorized as having normal (0-10) or abnormal (11-24) ESS and characterized by changes in ESS over time: normal-normal, normal-abnormal, abnormal-abnormal, and abnormal-normal. Cox proportional hazards models and elbow plots were conducted to evaluate magnitude of and thresholds for risk of 5-year all-cause mortality adjustment for age and sex. Results At baseline, qualifying Veterans were mostly white (74.2%) and male (92.2%) with a mean age of 55.8 ± 13.3 (N = 21,605). One quarter experienced all-cause mortality within five years of their second exam (25.9%). Veterans with abnormal ESS at the second exam had a 6% greater risk of five-year all-cause mortality (aHR: 1.06; 95%CI:1.00,1.11) than those with normal ESS, after adjusting for age and sex. Mortality risk was 13% higher among those converting from normal-abnormal (aHR: 1.13; 95%CI: 1.08,1.32), compared to normal-normal, particularly among those 60 years (aHR: 1.20; 95%CI:1.08,1.32), after adjustment. Regardless of baseline ESS, participants whose score increased over 3-points had significantly higher risk of five-year mortality compared to lesser changes (aHR: 1.08; 95% CI: 1.01, 1.16), which was intensified among those 60 years of age and over (aHR: 1.14, 95% CI: 1.05, 1.23), after adjustment. Conclusion These results suggest that abnormal ESS may serve as a clinical marker for increased risk of 5-year all-cause mortality. Providers should pay particular attention to ESS increases over 3-points, particularly among those 60 and older. Support (if any) NHLBI K25 HL152006 [J.R.]; ZOLL Respicardia (31002) [A.S.], AHBPCE, FY2024-002 [J.R.]; and IQuESt F&A (CIN 13-413) at the Michael E. DeBakey VA Medical Center, and Baylor College of Medicine in Houston, TX.
No takes yet. Share an insight, caveat, or question.
Bay et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: